BACKGROUND: Fingolimod, an oral sphingosine 1-phosphate receptor immunomodulator, is approved in Europe for people with multiple sclerosis (pwMS) with highly active disease despite a full and adequate course of treatment with ≥ 1 disease-modifying therapy or patients with rapidly evolving severe relapsing-remitting MS. GOLEMS, a national, multicenter, non-interventional, single-arm, real-world study showed a favorable benefit-risk profile of 12-month treatment with fingolimod in pwMS in the Czech Republic. Here, we evaluated the long-term effectiveness and safety of fingolimod and its impact on disability progression and work capability for up to 48 months in pwMS. METHODS: The endpoints assessed were the incidence and severity of MS relapses in fingolimod-treated patients and the proportion of relapse-free patients up to 48 months of fingolimod treatment, change from baseline in the Expanded Disability Status Scale (EDSS) score, and change from baseline in work capability assessment. Efficacy outcomes were analyzed in the completed and efficacy sets, and safety was evaluated in all the enrolled patients. RESULTS: Of 240 enrolled patients, 237 were included into efficacy set. Patients with a minimum of a 12-month observation period in the core study who continued fingolimod treatment, were eligible to participate in the extension phase. Of 211 patients enrolled in extension study, 155 were evaluated in the completed set. Based on analysis of 48-month period of fingolimod treatment, 95/237 patients (40.1%) in the efficacy set, 54/155 (34.8%) in the completed set were free of relapses. The majority of relapses reported were moderate in intensity. Mean EDSS score remained stable throughout 48-month study period (Baseline, 3.4; Month 48, 3.6). No trend was observed in changes in work capability assessment or number of missed days of work. Of 240 enrolled patients, 147 (61.3%) had ≥ 1 treatment-emergent adverse event (AE) and 20 (8.3%) reported serious AEs. In total, 45 patients (18.8%) permanently discontinued treatment because of AEs related to study drug; two patients reported pregnancy after treatment initiation and subsequently discontinued the treatment; no deaths were reported. CONCLUSION: GOLEMS study demonstrated the sustained effectiveness and manageable safety profile of fingolimod under real-world conditions over 48 months in patients with MS. TRIAL REGISTRATION: Not applicable.

ANOVA CRO s r o Zelená 2002 21a 160 00 Prague 6 Dejvice Prague Czech Republic

MS Center Department of Neurology and Center of Clinical Neuroscience 1st Faculty of Medicine and General University Hospital Prague Charles University Katerinska 30 12000 Praha 2 Prague Czech Republic

Novartis s r o Prague Czech Republic

Zobrazit více v PubMed

Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33(2):91–101. doi: 10.1097/WNF.0b013e3181cbf825. PubMed DOI PMC

Compston A, Coles A. Multiple sclerosis. Lancet (London, England) 2002;359(9313):1221–1231. doi: 10.1016/S0140-6736(02)08220-X. PubMed DOI

National MS Society . MS Prevalence FAQs. 2019.

Merkel B, Butzkueven H, Traboulsee AL, et al. Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis. a systematic review. Autoimmunity reviews. 2017;16(6):658–665. doi: 10.1016/j.autrev.2017.04.010. PubMed DOI

Derwenskus J. Current disease-modifying treatment of multiple sclerosis. Mt Sinai J Med. 2011;78(2):161–175. doi: 10.1002/msj.20239. PubMed DOI

GILENYA [Summary of Product Characteristics]. Nuremberg: Novartis Pharma GmbH; 2020. https://www.ema.europa.eu/en/documents/product-information/gilenya-epar-product-information_en.pdf.

Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401. doi: 10.1056/NEJMoa0909494. PubMed DOI

Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Neurology. 2014;13(6):545–556. doi: 10.1016/S1474-4422(14)70049-3. PubMed DOI

Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–415. doi: 10.1056/NEJMoa0907839. PubMed DOI

Kappos L, O'Connor P, Radue EW, et al. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology. 2015;84(15):1582–1591. doi: 10.1212/WNL.0000000000001462. PubMed DOI PMC

Cohen JA, Khatri B, Barkhof F, et al. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatr. 2016;87(5):468–475. doi: 10.1136/jnnp-2015-310597. PubMed DOI PMC

Cohen JA, Tenenbaum N, Bhatt A, et al. Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results. Ther Adv Neurol Disord. 2019;12:1756286419878324. doi: 10.1177/1756286419878324. PubMed DOI PMC

Ziemssen T, Hillert J, Butzkueven H. The importance of collecting structured clinical information on multiple sclerosis. BMC Med. 2016;14:81. doi: 10.1186/s12916-016-0627-1. PubMed DOI PMC

Ticha V, Kodym R, Pocikova Z, et al. Real-world outcomes in fingolimod-treated patients with multiple sclerosis in the Czech Republic: results from the 12-month GOLEMS study. Clin Drug Investig. 2017;37(2):175–186. doi: 10.1007/s40261-016-0471-2. PubMed DOI PMC

World Medical Association World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013;310(20):2191–2194. doi: 10.1001/jama.2013.281053. PubMed DOI

Ziemssen T, Lang M, Tackenberg B, et al. Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany. Neurology neuroimmunology & neuroinflammation. 2019;6(3):e548. doi: 10.1212/NXI.0000000000000548. PubMed DOI PMC

Ziemssen T, Albrecht H, Haas J, et al. 4 years PANGAEA: effectiveness update of a 5 year non-interventional study on the daily use of fingolimod in Germany. Mult Scler J. 2016;22(3):1–306.